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Abstract
Background. Smoking prevalence is higher amongst individuals with schizophrenia and
depression compared with the general population.Mendelian randomisation (MR) can examine
whether this association is causal using genetic variants identified in genome-wide association
studies (GWAS).
Methods. We conducted two-sample MR to explore the bi-directional effects of smoking
on schizophrenia and depression. For smoking behaviour, we used (1) smoking initiation
GWAS from the GSCAN consortium and (2) we conducted our own GWAS of lifetime
smoking behaviour (which captures smoking duration, heaviness and cessation) in a sample
of 462690 individuals from the UK Biobank. We validated this instrument using positive con-
trol outcomes (e.g. lung cancer). For schizophrenia and depression we used GWAS from the
PGC consortium.
Results. There was strong evidence to suggest smoking is a risk factor for both schizophrenia
(odds ratio (OR) 2.27, 95% confidence interval (CI) 1.67–3.08, p < 0.001) and depression
(OR 1.99, 95% CI 1.71–2.32, p < 0.001). Results were consistent across both lifetime smoking
and smoking initiation. We found some evidence that genetic liability to depression increases
smoking (β = 0.091, 95% CI 0.027–0.155, p = 0.005) but evidence was mixed for schizophrenia
(β = 0.022, 95% CI 0.005–0.038, p = 0.009) with very weak evidence for an effect on smoking
initiation.
Conclusions. These findings suggest that the association between smoking, schizophrenia and
depression is due, at least in part, to a causal effect of smoking, providing further evidence for
the detrimental consequences of smoking on mental health.
Introduction
Smoking is a major risk factor for lung cancer, cardiovascular and respiratory diseases making it
the leading cause of preventable death worldwide (World Health Organization, 2011). In devel-
oped nations, smoking is more common amongst individuals with mental health conditions
(Coulthard, Farrell, Singleton, & Meltzer, 2002; Lasser et al., 2000; Lawrence, Mitrou, &
Zubrick, 2009; McClave, McKnight-Eily, Davis, & Dube, 2010), in particular schizophrenia
(Royal College of Physicians, 2013) and depression (Byers et al., 2012; Leung, Gartner,
Dobson, Lucke, & Hall, 2011; Tjora et al., 2014). In the UK, estimates suggest that up to 45%
of individuals with schizophrenia, and 31% of individuals with depression smoke (Royal
College of Physicians, 2013), compared with around 15% of the general population (Office
for National Statistics, 2019). Individuals with mental health conditions smoke more heavily
(Coulthard et al., 2002) and experience up to 18 years reduced life expectancy compared with
the general population (Chang et al., 2011; Royal College of Physicians, 2013). Much of this
reduction can be explained by smoking-related diseases (Royal College of Physicians, 2013),
making it important to understand the relationship between smoking and mental health.
It is often assumed that the association between mental health and smoking can be
explained by a self-medication model – that is, symptoms of mental illness, or side effects
of psychiatric medications, are alleviated by the chemical properties of tobacco (Desai,
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Seabolt, & Jann, 2001; Khantzian, 1997; Lerman et al., 1996;
Levin, Wilson, Rose, & McEvoy, 1996). However, observational
evidence cannot determine whether the association between
smoking and mental health is causal or the result of confounding
(Lawlor, Harbord, Sterne, Timpson, & Davey Smith, 2008).
Furthermore, traditional observational evidence cannot robustly
identify the direction of causation (Lawlor et al., 2008), and
there is growing evidence to suggest that smoking may be a causal
risk factor for poor mental health. The genome-wide association
study (GWAS) of schizophrenia conducted by the Psychiatric
Genomics Consortium (PGC) found that variants in the gene
cluster CHRNA5-A3-B4 were associated with increased schizo-
phrenia risk (Ripke et al., 2014). These variants are known to
be strongly associated with heaviness of smoking (Munafò et al.,
2012; Thorgeirsson et al., 2008; Tobacco Consortium, 2010;
Ware, van den Bree, & Munafò, 2011). Therefore, one interpret-
ation is a possible causal effect of smoking on schizophrenia
(Gage & Munafò, 2015). Furthermore, there is evidence of genetic
correlations between smoking, schizophrenia and depression
(Hartz et al., 2018; Liu et al., 2019) warranting further investiga-
tion of possible causal effects. Prospective observational studies
using related individuals to control for genetic and environmental
confounding have suggested a dose–response effect of smoking on
schizophrenia (Kendler, Lönn, Sundquist, & Sundquist, 2015) and
depression (Kendler et al., 1993). Meta-analyses show further evi-
dence for an increased relative risk of schizophrenia in smokers
over non-smokers (Gurillo, Jauhar, Murray, & MacCabe, 2015;
Scott et al., 2018) and a reduction in depressive symptoms follow-
ing smoking cessation (Taylor, McNeill et al., 2014). Although
these studies suggest a potential causal effect, more robust meth-
ods are required to triangulate evidence and allow for stronger
causal inference (Munafò & Davey Smith, 2018).
One possible way to overcome bias from residual confounding
and reverse causation is Mendelian randomisation (MR) (Davey
Smith & Ebrahim, 2003). This method uses genetic variants to
proxy for an exposure in an instrumental variable analysis to esti-
mate the causal effect on an outcome (Lawlor et al., 2008). Previous
MR studies have failed to show any clear evidence for an effect of
smoking on depression (Bjørngaard et al., 2013; Taylor, Fluharty et
al., 2014; Wium-Andersen, Ørsted, & Nordestgaard, 2015) and
show suggestive but inconclusive evidence for an effect of smoking
on schizophrenia (Gage et al., 2017; Wium-Andersen et al., 2015).
However, the genetic instruments for smoking used in these
MR studies are limited, only capturing individual aspects of smok-
ing behaviour and only having identified limited numbers of
suitable genetic variants (Bjørngaard et al., 2013; Gage et al.,
2017; Taylor, Fluharty et al., 2014; Wium-Andersen et al., 2015).
Furthermore, any instrument for smoking heaviness requires strati-
fying samples into smokers and non-smokers. Stratification is not
possible using the most common MR method, two-sample MR. In
two-sample MR, single-nucleotide polymorphism (SNP)-exposure
and SNP-outcome effects are estimated in two independent sam-
ples and the effect sizes are obtained from GWAS summary statis-
tics. Therefore, in this context stratification is not possible because
GWAS summary data do not provide individual level data regard-
ing smoking status.
Here we improve upon previous MR studies of smoking and
mental health in two ways: (1) by using an updated instrument
for smoking initiation which comprises 378 SNPs (Liu et al.,
2019) and (2) we develop a novel genetic instrument for lifetime
smoking exposure that takes into account smoking status (i.e. ever
and never smokers), and among ever smokers takes into account
smoking duration, heaviness and cessation. This instrument can
therefore capture smoking behaviours beyond initiation and can
be used in unstratified samples of smokers and non-smokers.
By using the results of these different MR analyses together and
triangulating across multiple methods, we aim to determine
whether the observational associations between smoking, schizo-
phrenia and depression are likely causal, and the directionality of
these relationships.
Methods
Data sources and genetic instruments
Smoking initiation
The most recent GWAS of smoking initiation from the GSCAN
consortium identified 378 conditionally independent genome-
wide significant SNPs in a sample of 1 232 091 individuals of
European ancestry (Liu et al., 2019). The 378 SNPs explain 2%
of the variance in smoking initiation (Liu et al., 2019). When
smoking initiation was the outcome, summary statistics without
23andMe (N = 599 289) were used.
Lifetime smoking
To capture smoking heaviness and duration as well as smoking
initiation, we generated a lifetime smoking measure using data
from the UK Biobank. The UK Biobank is a national health
research resource of 502 647 participants aged 40–69 years,
recruited from across the UK between 2006 and 2010 (http://
www.ukbiobank.ac.uk). Our sample consisted of 462 690 indivi-
duals of European ancestry who had phenotype data and passed
genotype inclusion criteria (54% female; mean age = 56.7 years;
S.D. = 8.0 years). Overall, 30% of the sample had ever smoked
(8% current smokers and 22% former smokers).
Measures of smoking. Smoking measures available in the UK
Biobank were self-reported and collected at initial assessment.
They included: smoking status (current, former, never – field
20116), age at initiation in years (fields 3436/2867), age at cessa-
tion in years (field 2897) and number of cigarettes smoked per
day (fields 3456/2887). Anyone self-reporting to smoke more
than 100 cigarettes per day was contacted for confirmation.
Hand-rolled cigarette smokers were told 1 g of tobacco equates
to one cigarette. We calculated duration of smoking and time
since cessation. UK Biobank removed individuals smoking fewer
than 1 or more than 150 cigarettes a day.
Construction of the lifetime smoking index. Following the
method outlined by Leffondré, Abrahamowicz, Xiao, and
Siemiatycki (2006), we combined the smoking measures into a
lifetime smoking index along with a simulated half-life (τ) con-
stant. Half-life captures the exponentially decreasing effect of
smoking at a given time on health outcomes. The value of half-life
was determined by simulating the effects of lifetime smoking on
lung cancer and overall mortality in the UK Biobank. Both sug-
gested the best fitting value as 18. For full details on construction
of the lifetime smoking index see online Supplementary Note.
Genome-wide association study of lifetime smoking index. For
full details of genotyping and exclusion procedures see online
Supplementary Note. After excluding individuals who did not
pass genotype exclusions and who had missing phenotype data,
462 690 individuals remained for the GWAS. Of these individuals,
249 318 were never smokers (54%), 164 649 were former smokers
(36%) and 48 723 (11%) were current smokers. The mean value of
lifetime smoking score was 0.359 (S.D. = 0.694). GWAS was
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conducted using the UK Biobank GWAS pipeline set-up for the
MRC Integrative Epidemiology Unit (Elsworth et al., 2017).
BOLT-LMM was used to conduct the analysis (Loh et al.,
2015), which accounts for population stratification and relatedness
using linear mixed modelling. Genotyping chip and sex were
included as covariates. As a sensitivity analysis, we reran the
GWAS without controlling for genotype chip because the UK
BiLEVE sub-sample (which used a different genotyping chip) was
selected on the basis of smoking status. Genome-wide significant
SNPs were selected at p < 5 × 10−8 and were clumped to ensure inde-
pendence at linkage disequilibrium (LD) r2 = 0.001 and a distance of
10 000 kb using the TwoSampleMR package (Hemani et al., 2018).
Instrument generated. Our GWAS of lifetime smoking identi-
fied 126 independent, genome-wide significant SNPs (see Fig. 1
and online Supplementary Table S1). A standard deviation
increase in the lifetime smoking score is equivalent to an individ-
ual smoking 20 cigarettes a day for 15 years and stopping 17 years
ago or an individual smoking 60 cigarettes a day for 13 years and
stopping 22 years ago. We validated our instrument in an inde-
pendent sample and using positive control outcomes of lung
cancer, coronary heart disease and hypomethylation at the aryl-
hydrocarbon receptor repressor site cg05575921 because smoking
has been robustly shown to predict these outcomes (WHO, 2011;
Zeilinger et al., 2013). For further details of these validations see
the online Supplementary Note.
Schizophrenia
We used summary data from the PGC consortium GWAS, which
comprises 36 989 cases and 113 075 controls of European and East
Asian ancestry (Ripke et al., 2014). Cases were a combination of
individuals with schizophrenia and schizoaffective disorder, mostly
diagnosed by clinicians, but some samples used research-based
assessment. The ascertainment method did not affect GWAS
results (Ripke et al., 2014). A sensitivity analysis was performed
using the GWAS summary data meta-analysed with a further 11
260 cases and 24 542 controls (Pardiñas et al., 2018). The genetic
instrument for schizophrenia came from the PGC GWAS, which
identified 114 independent SNPs at 108 loci explaining around
3.4% of the variance in schizophrenia liability (Ripke et al., 2014).
Depression
For depression, we used GWAS summary data from the PGC for
major depression, which comprises 130 664 major depression
cases and 330 470 controls of European ancestry (Wray et al.,
2018). Cases were either diagnosed with major depressive disorder
(MDD) on inpatient or medical health records or self-reported
having a diagnosis or treatment for depression. Therefore, the
authors use the term major depression over diagnosed MDD
(Wray et al., 2018). 23andMe data (75 607 cases and 231 747 con-
trols) were excluded when major depression was the outcome
because genome-wide summary statistics are not available with
23andMe data included. The genetic instrument for major depres-
sion from the PGC GWAS was 40 genome-wide significant SNPs
which explain 1.9% of the variance in liability (Wray et al., 2018).
Statistical analysis
MR analyses were run using the MR Base R package (Hemani et al.,
2018; R. Core Team, 2014) and compared across five different meth-
ods: inverse-variance weighted, MR Egger (Bowden, Davey Smith, &
Burgess, 2015), weighted median (Bowden, Davey Smith, Haycock, &
Burgess, 2016), weighted mode (Hartwig, Smith, & Bowden, 2017)
and MR RAPS (Zhao, Wang, Hemani, Bowden, & Small, 2018).
Each of these methods makes slightly different assumptions about
the nature of pleiotropy and therefore a roughly consistent point esti-
mate across the multiple methods provides the strongest evidence of
causal inference (Lawlor, Tilling, & Davey Smith, 2016), with the
Inverse variance weighted (IVW) method being the main analysis
and each other method providing a sensitivity analysis. For additional
details on each of the methods see online Supplementary Table S12.
Two-sample MR analysis was run bi-directionally, first with smoking
as the exposure and then as the outcome. To test the suitability of the
MR Egger method, the I2GX statistic was calculated to quantify the
degree of regression dilution bias due to measurement error of
SNP-exposure effects (Bowden et al., 2016). We also calculated the
mean F statistic as an indicator of instrument strength. Steiger filter-
ing was conducted to confirm the direction of effect (Hemani,
Tilling, & Davey Smith, 2017). If a SNP from the instrument was
unavailable in the outcome, an attempt to find proxies was made
with a minimum LD r2 = 0.8 and palindromic SNPs were aligned
with Minor allele frequency < 0.3.
Results
Bi-directional MR analyses provided strong evidence that higher
lifetime smoking increases risk of both schizophrenia [IVW:
odds ratio (OR) 2.27, 95% confidence interval (CI) 1.67–3.08, p
< 0.001] and depression (IVW: OR 1.99, 95% CI 1.71–2.32, p <
0.001) (see Table 1), with consistent direction of effect across all
five MR methods. The same was seen for smoking initiation as
Fig. 1. Manhattan plot of genome-wide association study of lifetime smoking index (N = 462 690). The x-axis represents chromosomal position and the y-axis repre-
sents −log10 p value for the association of each SNP with the lifetime smoking index using an additive model and linear regression. The dashed line indicates the
genome-wide level of significance ( p < 5 × 10−8) and genome-wide significant SNPs are indicated in red.
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the instrument on schizophrenia (IVW: OR 1.53, 95% CI 1.35–
1.74, p < 0.001) and depression (IVW: OR 1.54, 95% CI 1.44–
1.64, p < 0.001) (see Table 1). MR Egger results are the least reliable
due to low I2GX (see online Supplementary Table S3). There was also
evidence of a consistent but smaller effect of higher genetic liability
for schizophrenia on lifetime smoking (IVW: β = 0.022, 95% CI
0.005–0.038, p = 0.009) and of genetic liability for depression
on lifetime smoking (IVW: β = 0.091, 95% CI 0.027–0.155,
p = 0.005) (see Table 2). These effects remained for depression
on smoking initiation (IVW: β = 0.083, 95% CI 0.039–0.127,
p < 0.001) but became even weaker and inconsistent across the
different methods for schizophrenia on smoking initiation (IVW:
β = 0.010, 95% CI 0.000–0.021, p = 0.04) (see Table 2). Overall,
the effect was larger and more consistent for depression than for
schizophrenia. We saw similar effects using the more recent
meta-analysed GWAS for schizophrenia with an additional
11 260 cases (see online Supplementary Table S9). There was evi-
dence of significant heterogeneity (see online Supplementary
Table S4) but MR Egger intercepts suggest directional pleiotropy
is not biasing the estimates (see online Supplementary Table S5)
and Steiger filtering supported the conclusion that the effects oper-
ate in both directions (see online Supplementary Table S6). Given
that variants from the CHRNA5-A3-B4 gene complex were identi-
fied in both GWAS of lifetime smoking and schizophrenia, we con-
ducted a sensitivity analysis removing these variants and the effects
remained consistent (see online Supplementary Table S10).
A total of 14 260 cases and 15 480 controls from the UK
Biobank were included in the latest GWAS for major depression
(Wray et al., 2018) which could lead to bias from sample overlap
(Burgess et al., 2015). Therefore, this analysis was repeated using
summary data from an earlier GWAS of major depression (Ripke
et al., 2013), which showed a consistent direction of effect with
weaker statistical evidence, possibly due to reduced sample size
(N = 18 759) (see online Supplementary Table S7). Second, we
repeated this analysis with the recent meta-analysed GWAS
which includes broader definitions of depression including
self-declared (Howard et al., 2019). These summary data were
available with UK Biobank and 23andMe removed leaving a sam-
ple size of 500 199 (170 756 cases and 329 443 controls). The
results of this analysis are presented in online Supplementary
Table S11. They are relatively consistent with the main analysis,
showing slightly larger effects of depression on smoking and
slightly reduced effects of smoking on depression. Bi-directional
MR analyses were repeated using the GWAS of lifetime smoking
without controlling for genotyping chip and the same pattern of
results was observed (see online Supplementary Table S8). Further
sensitivity tests were conducted and are presented in online
Supplementary Figs S9–S20.
Discussion
We conducted a GWAS of lifetime smoking exposure which pro-
vides a novel genetic instrument that can be used in two-sample
MR of summary data without the need to stratify on smoking
status. We used this novel genetic instrument along with a new
instrument of smoking initiation to explore possible causal
Table 1. Two-sample MR analyses of the effect of smoking exposure on schizophrenia and depression
Exposure Outcome Method N SNP OR (95% CI) p value
Lifetime smoking Schizophrenia Inverse-variance weighted 125 2.27 (1.67–3.08) 1.36 × 10−07
MR Egger (SIMEX) 125 4.59 (1.49–14.11) 0.009
Weighted median 125 2.04 (1.57–2.64) 8.21 × 10−08
Weighted mode 125 1.71 (0.69–4.23) 0.25
MR RAPS 125 2.44 (1.84–3.25) 9.30 × 10−10
Lifetime smoking Depression Inverse-variance weighted 126 1.99 (1.71–2.32) 9.69 × 10−19
MR Egger (SIMEX) 126 1.09 (0.62–1.92) 0.77
Weighted median 126 1.97 (1.65–2.35) 3.00 × 10−14
Weighted mode 126 1.83 (1.19–2.81) 0.007
MR RAPS 126 1.99 (1.70–2.32) 2.76 × 10−18
Smoking initiation Schizophrenia Inverse-variance weighted 371 1.53 (1.35–1.74) 3.70 × 10−11
MR Egger (SIMEX) 371 1.35 (0.83–2.22) 0.23
Weighted median 371 1.38 (1.23–1.55) 3.44 × 10−08
Weighted mode 371 1.23 (0.74–2.06) 0.42
MR RAPS 371 1.63 (1.45–1.85) 4.46 × 10−15
Smoking initiation Depression Inverse-variance weighted 370 1.54 (1.44–1.64) 3.61 × 10−37
MR Egger (SIMEX) 370 1.36 (1.10–1.67) 0.004
Weighted median 370 1.46 (1.35–1.58) 4.62 × 10−21
Weighted mode 370 1.44 (1.10–1.89) 0.008
MR RAPS 370 1.54 (1.44–1.65) 1.31 × 10−35
SIMEX, simulation extrapolation, MR RAPS, robust adjusted profile score.
Note: Due to low regression dilution I2GX for lifetime smoking and smoking initiation (see online Supplementary Table S3), MR Egger SIMEX estimates should be interpreted with caution.
SIMEX-corrected estimates are unweighted.
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pathways between smoking, schizophrenia and depression. The
two-sample MR results provide strong evidence that smoking is
a risk factor for both schizophrenia and depression. This supports
prospective observational evidence controlling for genetic con-
founding (Kendler et al., 1993, 2015), as well as meta-analyses
of observational studies (Gurillo et al., 2015; Taylor, McNeill
et al., 2014) (although it should be noted that these meta-analyses
include estimates not adjusted for known confounders e.g. canna-
bis use). Effect sizes were similar to a more recent meta-analysis
that did adjust for multiple confounders and found a two-fold
increased risk of schizophrenia in smokers compared with non-
smokers (Scott et al., 2018). Some studies which adjust for poten-
tial confounders find the effect of smoking attenuates to the null
(Jones et al., 2018) or even becomes protective (Zammit et al.,
2003), demonstrating that there are likely to be substantial con-
founding effects in observational studies. Previous MR studies
have not found clear evidence to support smoking as a risk factor
for either schizophrenia or depression (Bjørngaard et al., 2013;
Gage et al., 2017; Taylor, Fluharty et al., 2014; Wium-Andersen
et al., 2015), but our approach offers greater power, captures mul-
tiple aspects of smoking behaviour and enables two-sample MR
analysis using summary data in unstratified samples. However,
it is not possible to precisely estimate from our results what pro-
portion of the observational association between smoking, schizo-
phrenia and depression is causal, or the population attributional
fraction of these disorders due to smoking.
In support of the self-medication hypothesis (Khantzian,
1997), we found evidence to suggest that genetic liability for
schizophrenia and depression increases lifetime smoking. This
supports previous observational evidence (Desai et al., 2001;
Lerman et al., 1996; Levin et al., 1996) and might explain why
smoking rates remain so high amongst individuals with schizo-
phrenia and depression compared with the general population
(Cook et al., 2014). However, evidence was stronger for self-
medication effects in depression than schizophrenia and when
using smoking initiation as the outcome rather than lifetime
smoking, effects attenuated to the null. Therefore, maybe any self-
medication effects of schizophrenia are only on heaviness and
duration of smoking (captured by the lifetime smoking index)
rather than initiation. However, it is important to note that the
effects might be weaker because MR methods typically capture
the long-term effects of exposures (Labrecque & Swanson,
2018) with self-medication potentially being more acute.
Alternatively the effects of schizophrenia and depression on life-
time smoking might be explained by the misattribution hypothesis.
This proposes that smokers misattribute the ability of cigarettes to
relieve withdrawal, to their ability to relieve symptoms of psycho-
logical distress (Parrott, 1999, 2003). For example, withdrawal
symptoms include depressed mood, anxiety and irritability, and
smoking a cigarette alleviates those symptoms (Hughes, 2007).
Since many withdrawal symptoms are similar to the negative symp-
toms of schizophrenia and mood symptoms in depression, their
Table 2. Two-sample MR analyses of the effect of schizophrenia and depression on smoking
Exposure Outcome Method N SNP β (95% CI) p value
Schizophrenia Lifetime smoking Inverse-variance weighted 102 0.022 (0.005–0.038) 0.009
MR Egger (SIMEX) – – –
Weighted median 102 0.015 (0.004–0.026) 0.009
Weighted Mode 102 0.016 (−0.014 to 0.045) 0.31
MR RAPS 102 0.018 (0.003–0.032) 0.015
Depression Lifetime smoking Inverse-variance weighted 34 0.091 (0.027–0.155) 0.005
MR Egger (SIMEX) – – –
Weighted median 34 0.100 (0.058–0.141) 2.77 × 10−06
Weighted mode 34 0.109 (0.037–0.182) 0.005
MR RAPS 34 0.078 (0.014–0.141) 0.016
Schizophrenia Smoking initiation Inverse-variance weighted 107 0.010 (0.000–0.021) 0.04
MR Egger (SIMEX) 107 −0.030 (−0.093 to 0.033) 0.35
Weighted median 107 0.003 (−0.006 to 0.012) 0.53
Weighted Mode 107 −0.008 (−0.033 to 0.017) 0.54
MR RAPS 107 0.008 (−0.002 to 0.017) 0.11
Depression Smoking initiation Inverse-variance weighted 34 0.083 (0.039–0.127) 2.32 × 10−04
MR Egger (SIMEX) – – –
Weighted median 34 0.077 (0.042–0.112) 1.55 × 10−05
Weighted mode 34 0.062 (0.007–0.117) 0.03
MR RAPS 34 0.077 (0. 037–0.117) 1.64 × 10−04
SIMEX, simulation extrapolation, MR RAPS, robust adjusted profile score.
Note: Due to low regression dilution I2GX (see online Supplementary Table S3), MR Egger estimates could not be conducted apart from for the effect of schizophrenia on smoking initiation,
where a weighted MR Egger SIMEX was conducted. Smoking initiation scores are given in βs by GSCAN calculated from the meta-analysed z-score statistic by assuming a prevalence for the
binary trait (Liu et al., 2019).
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alleviation by smoking could give rise to the strong belief that
smoking helps to alleviate mental health symptoms.
A potential biological mechanism for the bi-directional causal
effects of smoking, schizophrenia and depression could be neu-
roadaptations in the dopaminergic and serotonin systems.
Nicotine acts on nicotinic cholinergic receptors in the brain
stimulating the release of neurotransmitters including dopamine
and serotonin (Benowitz, 2010). Dopamine and serotonin dys-
function have been implicated in the aetiology of schizophrenia
and depression, respectively (Howes, McCutcheon, & Stone,
2015; Jakubovski, Varigonda, Freemantle, Taylor, & Bloch,
2015). It is plausible, therefore, that disruption of these pathways
has a causal effect on these disorders. Alternatively, cannabis use
could be a mediating mechanism for the effects of smoking on
schizophrenia and depression. In prospective studies, cigarette
smoking has been shown to increase risk of cannabis dependence
(Hindocha et al., 2015). There is strong evidence suggesting that
cannabis use increases the risk of psychosis and affective disorders
(Moore et al., 2007). This vertical pleiotropy does not violate the
assumptions of MR, but simply means there are intermediate
mechanisms operating between the exposure and the outcome.
However, the strong effects we observe for lifetime smoking sug-
gest that any mediating influence of cannabis use is likely to only
partially account for these effects, given the relatively low preva-
lence of cannabis use [e.g. annual prevalence in the UK of ∼7%
in 2010 (United Nations Office on Drugs and Crime
(UNODC), 2011)]. Multivariable MR analysis of tobacco and
cannabis use would help resolve this question.
Finally, although we are using the method of MR to provide
stronger causal inference, the best evidence of a causal effect
comes from many corroborating lines of evidence from study
designs with diverse assumptions. Looking at our current results
alongside previous literature, we conclude this strengthens evi-
dence for an effect of smoking on increased risk of depression
and schizophrenia. Future work should attempt to elucidate the
underlying mechanisms with a hope to intervene, inform public
health messages or further advance our knowledge on the aeti-
ology of mental illness. In particular, it will be important to con-
sider other constituents of tobacco smoke to determine whether it
is exposure to nicotine or some other constituent that increases
risk of schizophrenia and depression. This is particularly import-
ant in the context of the recent growth in electronic cigarette use.
Strengths and limitations
Our study is the first to generate a genetic instrument for lifetime
smoking behaviour in a large sample, which allows the use of two-
sample MR with summary data from unstratified samples to
answer questions about the association between smoking and
other health outcomes. However, there are some limitations
which should be noted. First, there is evidence to suggest that
even after seemingly controlling for population structure in
GWAS of samples as large as the UK Biobank, coincident apparent
structure remains (Haworth et al., 2019). This might confound the
association between smoking andmental health, increasing the risk
of false positives. As independent samples with adequate sample
size become available, the influence of structure should be further
explored. However, it is reassuring that our instrument predicted
lifetime smoking in an independent replication sample, where
such issues would not arise in the same manner.
Second, sample overlap in two-sample MR can bias results
towards the observational estimate (Burgess et al., 2015). There
was some sample overlap between the major depression GWAS
(Wray et al., 2018) and the UK Biobank (used to derive the life-
time smoking instrument and included in the smoking initiation
GWAS) meaning that the effects could be inflated. Therefore, a
sensitivity analysis was conducted using a previous GWAS of
major depression (Ripke et al., 2013) which showed the same dir-
ection of effect despite lower power. This gives us confidence in
the bi-directional effects of smoking and depression, despite sam-
ple overlap. This sensitivity analysis also addresses recent con-
cerns over the specificity of the most recent GWAS for major
depression (Cai et al., 2019). Comparing self-reported ‘seeking
help for depression’ with DSM-diagnosed MDD yielded different
results (Cai et al., 2019). However, the earlier GWAS of depression
did use Diagnostic and statistical manual diagnosed cases only
(Ripke et al., 2013) and showed the same direction of effect des-
pite lower power.
Third, including multiple aspects of smoking behaviour could
have introduced more potential for horizontal pleiotropy. The
more diffuse the definition of smoking, the more lifestyle factors
might be correlated, making it especially important to test for
horizontal pleiotropy. We conducted multiple sensitivity analyses
(which all make different and largely uncorrelated assumptions),
and all demonstrated the same direction of effect. This increases
our confidence that the results are not biased by pleiotropy.
Furthermore, MR Egger intercepts did not show evidence of
directional pleiotropy for schizophrenia or depression. However,
further work should still attempt to understand the biological
mechanisms underpinning the association to reduce the likeli-
hood of pleiotropic effects.
Fourth, schizophrenia and depression are disorders with an aver-
age age of onset around early to mid-adulthood (Office for National
Statistics, 2018; World Health Organization, 2018). Our measure
of lifetime smoking was generated using participants in the UK
Biobank aged over 40 years. Therefore, the causal pathway from
smoking to schizophrenia and depression risk might initially
seem unclear. However, we were not using participants’ smoking
behaviour at age 40, but rather retrospective lifetime smoking behav-
iour from age at initiation. It is plausible that smoking behaviour in
earlier life could increase risk of later mental health outcomes and
exacerbate symptoms, consequently causing more smokers than
non-smokers to seek a diagnosis. Furthermore, we saw consistent
effects when using smoking initiation as the exposure. Individuals
are more likely to initiate smoking prior to the average age at
onset of schizophrenia and depression, with 90% of individuals
initiating before 18 years of age (Centers for Disease Control and
Prevention, 2018). There has also been recent debate in the field
about the interpretation of time varying exposures in MR and one
way to minimise bias is to use average SNP effects on phenotype
across time, as we have done here with our lifetime smoking instru-
ment (Labrecque & Swanson, 2018). We recommend that future
studies wishing to examine the effects of smoking on an outcome
use multiple instruments for smoking behaviour with consistent
evidence across multiple instruments providing the strongest
evidence of a causal effect.
Fifth, there is a high degree of zero inflation in the distribution
of our lifetime smoking index scores with 54% of the sample
being never smokers and therefore receiving a score of zero. We
decided not to transform the variable given the desire to have
interpretable effect sizes for MR and we decided not to exclude
never smokers because our instrument is designed to be used in
two-sample MR without the need to stratify into smokers and
non-smokers. Despite the zero inflation, we see similar effects
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for lifetime smoking and smoking initiation suggesting that this
has not impaired the score. Sixth, the lifetime smoking score
was simulated using all-cause mortality and lung cancer as out-
comes. The pattern of association between smoking and lung can-
cer risk compared with risk for schizophrenia and depression is
likely to be different. However, increased mortality amongst indi-
viduals with schizophrenia and depression is in large part due to
smoking-related mortality (Royal College of Physicians, 2013).
The effects were modelled on all-cause mortality and lung cancer
but no difference to the best fitting value of half-life was observed.
We hope that using all-cause mortality as an outcome makes the
lifetime smoking instrument broadly applicable to exploring mul-
tiple outcomes. Furthermore, the same effects are observed using
smoking initiation as the exposure, which does not include the
simulated variable.
Finally, there is known selection bias in the UK Biobank sample,
with participants being more highly educated, less likely to be a
smoker and overall healthier than the general UK population
(Munafo, Tilling, Taylor, Evans, & Davey Smith, 2017). Of the 9
million individuals contacted, only ∼5% consented to take part
(Munafo et al., 2017). Due to the lack of representativeness in the
UK Biobank sample, prevalence and incidence rates will not reflect
underlying population levels and there is potential for collider bias.
If both smoking and liability for schizophrenia and depression
reduce the likelihood of participating in the UK Biobank, then
this would induce a negative correlation between schizophrenia or
depression and smoking. That is the opposite of the effects observed,
suggesting our estimates may, if anything, be conservative.
Conclusion
In conclusion, we improved upon previous MR studies of smoking
and mental health by using an updated instrument of smoking
initiation and by developing a novel genetic instrument of lifetime
smoking that can be used in two-sampleMRof summary datawith-
out stratifying on smoking status or reducing power. In two-sample
MR analysis, there was evidence of an effect between smoking and
mental health in both directions; however, the however, the effects
for depression on smoking were stronger than for schizophrenia on
smoking. Strong effects of smoking as a risk factor emphasises the
detrimental public health consequences of smoking, especially for
mental health, and the need to reduce smoking prevalence not
only to reduce the burden of physical illness, but also to reduce
the burden of mental illness.
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